Monoclonal antibody prevents HIV infection in monkeys, study finds outbreaknewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outbreaknewstoday.com Daily Mail and Mail on Sunday newspapers.
The National Institutes of Health has selected Tulane National Primate Research Center to lead a new partnership between the seven federally funded National Primate Research Centers to combine their efforts to accelerate promising COVID-19 vaccine and drug research.
The NIH contract, awarded at $1.7 million for the first year, has the potential to reach up to $6.5 million over a four-year funding period.
Tulane will play a leading role in coordinating the evaluation of promising COVID-19 vaccines and therapeutics for COVTEN (Coronavirus Vaccine and Therapeutic Evaluation Network). The partnership will standardize research protocols and methods of data collection, share preliminary data and best practices across centers, and minimize the use of nonhuman primates by having single control groups across multiple studies. The centers, which normally conduct research independently, aim to harmonize their studies to provide more useful comparative data.
Tulane University to lead national research partnership to speed up COVID-19 vaccine discoveries A COVID-19 researcher in the biosafety level 3 laboratory at the Tulane National Primate Research Center. (Source: Tulane University) By Nicole Mumphrey | February 3, 2021 at 1:55 PM CST - Updated February 3 at 1:56 PM
NEW ORLEANS (WVUE) -The National Institutes of Health has selected Tulane National Primate Research Center to lead a new partnership between the seven federally funded National Primate Research Centers to combine their efforts to accelerate promising COVID-19 vaccine and drug research.
The NIH contract, awarded at $1.7 million for the first year, has the potential to reach up to $6.5 million over a four-year funding period.